A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants [Immunology and Inflammation]

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in over 100 million infections and millions of deaths. Effective vaccines remain the best hope of curtailing SARS-CoV-2 transmission, morbidity, and mortality. The vaccines in current use require cold storage and sophisticated manufacturing capacity, which complicates their...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Immunology and Inflammation, Coronavirus (COVID-19) Biological Sciences Source Type: research